 "HC grants relief to Galderma against infringers using 'CETAPHIL' trademark")
The Bombay High Court has granted relief to Swiss pharmaceutical major Galderma Holdings in an intellectual property (IP) enforcement action against counterfeit products bearing its ‘CETAPHIL’ trademark. Galderma, acting through its Indian subsidiary Galderma India, had approached the Court seeking urgent measures to address large-scale counterfeiting of its products across online platforms and local markets.
On 18 June, the Court issued a John Doe injunction order, permitting the company to take immediate action against unidentified infringers. Following the order, search and seizure operations were carried out by a team from Khaitan and Co. on 2 July in collaboration with the police and Court Receivers. The enforcement team conducted searches at manufacturing and trading locations in New Delhi and Mumbai.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%